Levetiracetam treatment ameliorates LRRK2 pathological mutant phenotype. Issue 12 (27th September 2019)

• Record Type: Journal Article
• Authors: Rassu, Mauro; Biosa, Alice; Galioto, Manuela; Fais, Milena; Sini, Paola; Greggio, Elisa; Piccoli, Giovanni; Crosio, Claudia; Iaccarino, Ciro
• Is Part Of: Journal of cellular and molecular medicine. Volume 23:Issue 12(2019)
• Page Start: 8505
• Page End: 8510
• Publication Date: 2019-09-27
• Subjects: Levetiracetam -- LRRK2 -- Parkinson's disease -- SV2A; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.14674
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Mutations in leucine‐rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson's disease (PD). The LRRK2 physiological and pathological function is still debated. However, different experimental evidence based on LRRK2 cellular localization and LRRK2 protein interactors suggests that LRRK2 may be part and regulate a protein network modulating vesicle dynamics/trafficking. Interestingly, the synaptic vesicle protein SV2A is part of this protein complex. Importantly, SV2A is the binding site of the levetiracetam (LEV), a compound largely used in human therapy for epilepsy treatment. The binding of LEV to SV2A reduces the neuronal firing by the modulation of vesicle trafficking although by an unclear molecular mechanism. In this short communication, we have analysed the interaction between the LRRK2 and SV2A pathways by LEV treatment. Interestingly, LEV significantly counteracts the effect of LRRK2 G2019S pathological mutant expression in three different cellular experimental models. Our data strongly suggest that LEV treatment may have a neuroprotective effect on LRRK2 pathological mutant toxicity and that LEV repositioning could be a viable compound for PD treatment.